Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 8, 2008, Pages 2953-2956

  Goldenberg, Naila ^a   Racine, Michael S ^a   Thomas, Pamela ^c   Degnan, Bernard ^d   Chandler, William ^a,b   Barkan, Ariel ^a,b,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Indiana Hemophilia and Thrombosis Center   (United States)

^d ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACROMEGALY; ADD ON THERAPY; ADOLESCENT; ARTICLE; CASE REPORT; CASE STUDY; DESCRIPTIVE RESEARCH; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACIES; FEMALE; FOLLOW UP; GIGANTISM; GROWTH HORMONE RELEASE; GROWTH RATE; HUMAN; HYPERHIDROSIS; HYPERTROPHY; HYPOPHYSIS ADENOMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SNORING; TREATMENT RESPONSE; TUMOR VOLUME; UNIVERSITY HOSPITAL;

EID: 49249088690     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2283     Document Type: Review

References (17)

1. Eugster EA, Pescovitz OH, Gigantism J 1999 Clin Endocrinol Metab 84:4379-4384
2. Zampieri P, Scanarini M, Sicolo N, Andrioli G, Mingrino S 1983 The acromegaly gigantism syndrome. Report of four cases treated surgically. Surg Neurol 20:498-503
3. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G 2006 Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-1403
4. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
5. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B 2005 Pegvisomant therapy in pituitary gigantism: successful treatment in a 12 year old girl. Eur J Endocrinol 153:195-201
6. Müssig K, Gallwitz B, Honegger J, Strasbuerg CJ, Bidlingmaier M, Machicao F, Bornemann A, Ranke MB, Häring HU, Petersenn S 2007 Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. Exp Clin Endocrinol Diabetes 115:198-202
7. Ali O, Banerjee S, Kelly DF, Lee PDK 2007 Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary 10:359-364
8. Greulich W, Pyle S 1999 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Palo Alto, CA: Stanford University Press
9. Tanner JM, Landt KW, Cameron N, Carter BS, Patel J 1983 Prediction of adult height from height and bone age in childhood. A new system of equations (TW Mark II) based on a sample including very tall and very short children. Arch Dis Child 58:767-776
10. Tanner JM, Whitehouse RH, Marshall WA, Carter BS 1975 Prediction of adult height from height, bone age, and occurrence of menarche, at ages 4 to 16 with allowance for midparent height. Arch Dis Child 50:14-26
11. Wales JKH, Wit J-M, Rogol A 2003 Pediatric endocrinology and growth. 2nd ed. Philadelphia: Saunders
12. Parkinson C, Trainer PJ 1999 Growth hormone receptor antagonists therapy for acromegaly. Bailleres Best Pract Res Clin Endocrinol Metab 13:419-430
13. Laron Z, Sarel R, Pertzelan A 1980 Puberty in Laron type dwarfism. Eur J Pediatr 134:79-83
14. Aynsley-Green A, Zachmann M, Prader A 1976 Interrelation of the therapeutic effects of growth hormone and testosterone on growth in hypopituitarism. J Pediatr 89:992-999
15. Borski RJ, Tsai W, DeMott-Friberg R, Barkan AL 1996 Regulation of somatic growth and the somatotropic axis by gonadal steroids: primary effect on insulin-like growth factor 1 gene expression and secretion. Endocrinology 137:3253-3259
16. Trainer PJ 2003 Lessons from 6 years of GH receptor antagonist therapy for acromegaly. J Endocrinol Invest 26:44-52
17. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect of IGF-1 levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477